InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,549.90
(
0.74%
)
US TECH 100
19,784.80
(
0.73%
)
Dow Jones
39,293.98
(
-0.04%
)
Brent Oil
87.58
(
0.28%
)
Bitcoin
56,490.38
(
-0.87%
)
Post# of 252490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Titan V

Send PM Follow Ignore
Followers 31
Posts 3757
Boards Moderated 0
Alias Born 01/29/2012

Titan V

Re: None

Monday, 09/18/2017 11:36:33 AM

Monday, September 18, 2017 11:36:33 AM

Post# of 252490
AbbVie Announces Positive Topline Results from Phase 3 Trial Evaluating VENCLEXTA™/VENCLYXTO™ (Venetoclax) Tablets in Combination with Rituxan® (rituximab) for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
http://www.prnewswire.com/news-releases/abbvie-announces-positive-topline-results-from-phase-3-trial-evaluating-venclextavenclyxto-venetoclax-tablets-in-combination-with-rituxan-rituximab-for-the-treatment-of-patients-with-relapsedrefractory-chronic-lymphocytic-300520916.html
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up